Skip to main content
. 2021 Jun 10;11:634920. doi: 10.3389/fonc.2021.634920

Figure 3.

Figure 3

Somatic mutation profiles of pre-ICPi, post-ICPi/pre-BRAFi, and post-BRAFi. (A) The heatmap shows an overview of mutations in pre-ICPi, post-ICPi/pre-BRAFi, and post-BRAFi within liquid biopsy, pericardial effusion biopsy, and left supraclavicular lymph node. (B) Clonal evolution in liquid biopsy dynamic monitoring (Upper) and mean variant allele frequency (VAF) change (Lower) during immunotherapy and BRAF inhibitor Vemurafenib treatment. Variants from cfDNA using Bayesian cluster with PyClone. CCF, cancer cell fraction; ICPi, immune check-point inhibitor; BRAFi, BRAF inhibitor.